Bluejay Diagnostics (BJDX) Shares Outstanding (Weighted Average) (2020 - 2026)

Bluejay Diagnostics has disclosed Shares Outstanding (Weighted Average) across 7 years of filings, most recently posting $984668.0 for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $984668.0, up 610.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $984668.0 (up 610.94% YoY), and the FY2025 annual result was $449043.0, up 879.42% from the prior year.
• Shares Outstanding (Weighted Average) came in at $984668.0 for Q1 2026 at Bluejay Diagnostics, up from $449043.0 in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $68.6 million in Q3 2024 to a low of $2741.0 in Q4 2023.
• The 5-year median for Shares Outstanding (Weighted Average) is $138503.0 (2025), against an average of $4.6 million.
• Across the five-year window, Shares Outstanding (Weighted Average) sank 99.91% in 2022 and jumped 88706.37% in 2024, its largest moves.
• Bluejay Diagnostics' Shares Outstanding (Weighted Average) stood at $1.0 million in 2022, then sank by 99.73% to $2741.0 in 2023, then soared by 1572.67% to $45848.0 in 2024, then jumped by 879.42% to $449043.0 in 2025, then soared by 119.28% to $984668.0 in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $984668.0 (Q1 2026), $449043.0 (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.